Newsfeeds - Spark Newswire

1 minute read

Cathie Wood’s ARK Invest Posts Fund Sales For Tuesday, June 15, 2021: PSTI, NVS, SRPT, TAK, ICE, TER, RAVN, GLEO, NET

Today, 9:48 AM

Pluristem Therapeutics (PSTI) - 1,131 Shares Novartis (NVS) - 139,576 Sarepta Therapeutics (SRPT) - 48,004 Takeda Pharmaceutical (TAK) - 228,234 Intercontinental Exchange (ICE) - 196,304 Teradyne (TER) -

GLEO

16 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For June 15, 2021

By Benzinga Insights

Today, 9:48 AM

ACRS

2 minute read

Uncategorized

Sarepta Therapeutics Reports Its Duchenne Muscular Dystrophy Treatment Showed Expression, Consistent Profile Using Co.’s Commercial Process Material

By Benzinga Newsdesk

Today, 9:48 AM

Results from the first 11 participants enrolled in Study 9001-103 ENDEAVOR showed robust transduction, delivering mean vector genome copies of 3.87 per nucleus Treated patients achieved mean micro-dystrophin

SRPT

2 minute read

Uncategorized

Cathie Wood Buys $26M Disney Shares And Sells $13M In Netflix: What You Need To Know

By Rachit Vats

Today, 9:48 AM

Cathie Wood-led Ark Investment Management on Friday bought 150,556 shares, worth about $26.15 million, in Walt Disney Co (NYSE: DIS), marking its debut in the media and entertainment company as analysts pointed to benefits from the reopening of theme parks in 2021.

ACCD

2 minute read

Uncategorized

Cathie Wood Sheds $33.6M Alibaba Shares On Earnings Day

By Rachit Vats

Today, 9:48 AM

Cathie Wood-led Ark Investment Management on Thursday shed 162,840 shares, worth about $33.6 million, in Alibaba Group Holding (NYSE: BABA) after the company posted its first operating loss as a listed company, as a record regulatory fine it was

ADYEY

2 minute read

Uncategorized

Cathie Wood Piles Up Palantir For Third Day In A Row, Adding $39M Worth Of Shares

By Rachit Vats

Today, 9:48 AM

Cathie Wood-led Ark Investment Management on Wednesday snapped up 2.07 million shares, worth about $39 million, in Palantir Technologies Inc (NYSE: PLTR), on a day the stock reversed the earnings-driven gains of the previous session.

ADPT

7 minute read

Uncategorized

The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron

By Shanthi Rexaline

Today, 9:48 AM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 11)

ABIO

26 minute read

Uncategorized

Earnings Scheduled For May 5, 2021

By Benzinga Insights

Today, 9:48 AM

Companies Reporting Before The Bell • Monmouth Real Estate (NYSE:MNR) is likely to report earnings for its second quarter.

AAWW

1 minute read

Uncategorized

Monthly Dosing Of Sarepta’s Next-Gen Eteplirsen Can Potentially Achieve Over 10% Higher Dystrophin Expression In DMD Patients

By Vandana Singh

Today, 9:48 AM

Sarepta Therapeutics Inc (NASDAQ: SRPT) announced positive results from Part A in a tiny group of 4 patients of the MOMENTUM Phase 2…

SRPT

3 minute read

Uncategorized

Sarepta Therapeutics Reports Clinical Results From Phase 2 MOMENTUM Study Of SRP-5051 In Patients With Duchenne Muscular Dystrophy Amenable To Skipping Exon 51; Delivered Mean Exon Skipping Of 10.79% And Mean Dystrophin Expression Of 6.55%

By Bill Haddad

Today, 9:48 AM

Results suggest a highly potent next-generation treatment that could offer greater efficacy with less frequent dosing SRP-5051 dosed monthly at 30 mg/kg delivered mean exon skipping of 10.79% and mean

SRPT